Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in CRSwNP (CROWNS-2)
NCT05436275Phase 3Completed
- Sponsor
- Keymed Biosciences
- Start
- Aug 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyposis (CRSwNP) comparing CM310 with Placebo (2 arms). Primary endpoints: Nasal Polyps Score at 24 weeks and Nasal Congestion Score at 24 weeks. Started Aug 2022; status: completed.
02
Drugs
stapokibart
03
Conditions
chronic rhinosinusitis with nasal polyposis (CRSwNP)
Beyond the preview
Go deeper on NCT05436275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436275.